Vericel Stock News

Vericel press release (VCEL): Q4 GAAP EPS of $0.09 misses by $0.05.Revenue of $47.6M (+5.3% Y/Y) misses by $0.49M.Gross margin of 72%, compared to 74% in the fourth quarter…

Full-Year 2021 Total Revenue Growth of 26%

Vericel (NASDAQ:VCEL) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $0.14 (-44.0% Y/Y) and the consensus…

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2021 financial results and business highlights.

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the followin

Vericel Corporation (VCEL) entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network

Vericel Corporation <> is trading lower in morning hours after the company slashed its guidance for 2021 revenue growth to a range below the consensus.Ahead of its

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co

The 2021 Biotech Bear market is creating a huge investment opportunity, as fundamentally robust companies are trading at a deep bargain. With its two powerful cellular therapies, Vericel is enjoying s

Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Profitability This table compares Titan Pharmaceuticals and Vericels net margins, return on equity and return on []

Vericel Co. (NASDAQ:VCEL) Investment analysts at Truist Securiti issued their FY2023 EPS estimates for Vericel in a note issued to investors on Tuesday, December 21st. Truist Securiti analyst S. Brodovsky expects that the biotechnology company will earn $0.44 per share for the year. Several other equities analysts also recently commented on VCEL. Zacks Investment []

The post I think Vericel Corp is a buy appeared on BitcoinEthereumNews.com . Penn National Gaming: I like Penn National. I liked it low. I liked it high. I think Penn National is a winner. I think that its done a lot of

"Mad Money" host Jim Cramer rings the lightning round bell, which means he''s giving his answers to callers'' stock questions at rapid speed.

Vericel (NASDAQ:VCEL) had its target price reduced by analysts at Truist Securities from $55.00 to $52.00 in a research note issued on Tuesday, Analyst Ratings Network reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Truist Securities’ target price points to a potential upside of 28.49% from the stock’s current price. […]